Company / Capital Expenditures
TherapeuticsMD, Inc. Capital Expenditures History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$34.0K
FY2022
5-year range
$34.0K / $2.5M
FY2018-FY2022
Trend
-98.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 8 years, ranging from $30,962 in FY2016 to $2M in FY2021.
Based on SEC 10-K filings.
$34,000 in FY2022 with a 5-year CAGR of -27.1%.
Declined from $217,040 to $34,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -18.1%
- 5-Year CAGR
- -27.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -27.1%, indicating a declining trend.
- In FY2022, capital expenditures decreased 98.6% year-over-year.
- Peak capital expenditures was recorded in FY2021.
- Lowest capital expenditures in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $34.0K | -98.6% |
| FY2021 | $2.5M | +1028.8% |
| FY2020 | $217.0K | +251.1% |
| FY2019 | $61.8K | -84.4% |
| FY2018 | $396.2K | +139.7% |
| FY2017 | $165.3K | +433.7% |
| FY2016 | $31.0K | -24.1% |
| FY2015 | $40.8K | -38.6% |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026